STOCK TITAN

Crispr Therapeut - CRSP STOCK NEWS

Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.

Overview of CRISPR Therapeutics (CRSP)

CRISPR Therapeutics is a prominent biopharmaceutical company at the forefront of gene editing innovation. Utilizing its proprietary CRISPR/Cas9 platform, the company pioneers precise and transformative gene-based medicines aimed at treating serious, genetically defined diseases. With strategic emphasis on gene editing, transformative therapeutics, and precision medicine, CRISPR Therapeutics has established a unique position in the biotechnology ecosystem.

Core Technology and Scientific Foundation

The backbone of CRISPR Therapeutics is the revolutionary CRISPR/Cas9 system, a cutting-edge technology that allows for direct, accurate modifications to genomic DNA. This approach involves leveraging an RNA-guided DNA endonuclease to target specific gene sequences, facilitating edits that can correct genetic anomalies. The platform’s precision and adaptability have opened new avenues for addressing diseases that were previously considered intractable.

Therapeutic Programs and Disease Areas

The company has a comprehensive portfolio of therapeutic programs spanning multiple disease areas. Its research and clinical efforts concentrate on:

  • Hemoglobinopathies: Programs designed to modify genetic sequences critical to conditions such as sickle cell disease and transfusion-dependent beta-thalassemia, aiming to restore normal hemoglobin production.
  • Oncology and Immuno-Oncology: Advanced cell therapies, including allogeneic CAR T therapies, target various hematologic malignancies by harnessing the immune system to recognize and eradicate cancer cells.
  • Regenerative Medicine: Development of innovative approaches for tissue repair and regeneration, leveraging stem cell-derived therapies for diseases like Type 1 diabetes.
  • Rare and Autoimmune Diseases: Precision gene editing enables tailored interventions for underserved patient populations facing high unmet medical needs.

This diversified approach not only addresses a wide range of conditions but also underscores the company’s commitment to exploring the full potential of gene editing in medicine.

Collaborative Partnerships and Global Footprint

Recognizing the complexities underlying gene-based therapies, CRISPR Therapeutics has forged robust strategic collaborations with leading industry partners. These alliances facilitate accelerated development, manufacturing, and commercialization of transformative therapeutics. The company operates on a global scale, with research and development centers, as well as business offices strategically positioned across key regions in North America and Europe, ensuring its innovations reach a broad patient base.

Research and Development Excellence

With a strong focus on R&D, the company continuously refines its CRISPR/Cas9 platform and explores next-generation gene editing tools and delivery systems. Its ongoing clinical trials and investigational programs provide crucial insights into safety, efficacy, and the therapeutic potential of its candidates. This research-driven approach, combined with a rigorous scientific methodology, helps solidify the company’s reputation as an authority in the field of gene editing.

Industry Relevance and Competitive Positioning

CRISPR Therapeutics exemplifies technological mastery in the fast-evolving field of biomedicine. Its innovative platform not only catalyzes new treatment paradigms but also redefines standards for precision and safety in gene therapy. The company’s comprehensive development programs, coupled with its strategic partnerships, position it distinctly within a competitive landscape that includes other advanced biopharmaceutical innovators. Its methodical approach to research and a deep understanding of clinical challenges underscore its commitment to addressing some of the most daunting medical conditions.

Business Model and Market Strategy

The core of CRISPR Therapeutics' business model lies in its robust scientific platform, which supports a pipeline of diverse gene-editing programs. The company carefully balances in-house research with external collaborations to de-risk development and optimize resource allocation. By focusing on therapeutic areas with significant unmet needs, it targets markets where precision medicine can have the most pronounced impact. This integrated strategy ensures that CRISPR Therapeutics remains both innovative and adaptable to changing industry dynamics.

Commitment to Precision, Expertise, and Transparency

Transparency in scientific inquiry and commitment to regulatory rigor form the cornerstone of the company’s ethos. CRISPR Therapeutics approaches each clinical challenge with detailed risk assessments and well-defined safety profiles, ensuring that its innovations are both scientifically robust and ethically grounded. Such diligence not only reinforces its credibility but also instills confidence among stakeholders and the broader medical community.

Concluding Insights

In summary, CRISPR Therapeutics stands as a seminal player in the gene editing landscape, blending groundbreaking science with a strategic, diversified approach to disease treatment. Its focus on deploying the CRISPR/Cas9 platform across multiple therapeutic areas reflects both scientific ingenuity and a commitment to addressing complex medical challenges. For anyone seeking a comprehensive understanding of its business, the company provides an exemplary case study in translating gene editing technology into tangible, life-changing treatments.

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announced that Chief Operating Officer Julianne Bruno will step down from her position effective April 11, 2025, to pursue external opportunities. Bruno has served the company for six years, during which her leadership was important in advancing the company's hematology and oncology programs. CEO Samarth Kulkarni acknowledged her contributions in maturing the company's operating model and various cross-functional initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
-
Rhea-AI Summary

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's senior management team will deliver a presentation on March 3, 2025, at 10:30 a.m. ET.

Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'Events & Presentations' section. The presentation recording will remain available for replay on the company's website for 14 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences
-
Rhea-AI Summary

CRISPR Therapeutics reports Q4 and full year 2024 results, highlighting significant progress across its portfolio. The company's CASGEVY® treatment continues to gain momentum with more than 50 authorized treatment centers activated globally and over 50 patients having cells collected across all regions by end of 2024.

The company maintains a strong financial position with $1.9 billion in cash and equivalents as of December 31, 2024. Q4 2024 financial results show R&D expenses of $82.2 million (down from $95.1 million in Q4 2023) and G&A expenses of $18.1 million. The company reported a net loss of $37.3 million for Q4 2024, compared to net income of $89.3 million in Q4 2023.

Key developments include ongoing clinical trials for next-generation CAR T products CTX112™ and CTX131™, and in vivo gene editing candidates CTX310™ and CTX320™. The company also established a strategic partnership with Nkure Therapeutics for CTX112 development in India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.29%
Tags
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines for serious diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's senior management team will deliver a presentation on Wednesday, February 5, 2025, at 2:00 p.m. ET.

The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section. Interested parties can view the fireside chat through the investor relations portal at https://crisprtx.gcs-web.com/events. The recording will remain available for replay on the company's website for 14 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) has outlined its strategic priorities and anticipated milestones for 2025. The company is starting the year with approximately $1.9 billion in cash and marketable securities, driven by the successful launch of CASGEVY®. CASGEVY has seen strong global demand, with over 50 patients initiating cell collection and more than 50 Authorized Treatment Centers (ATCs) established globally.

Key priorities for 2025 include advancing pipeline candidates such as CTX112™ in oncology and autoimmune diseases, and CTX310™ and CTX320™ in cardiovascular indications. The company also focuses on next-generation gene editing and lipid nanoparticle (LNP) delivery platforms.

Significant updates are expected in 2025, including quarterly updates on CASGEVY, clinical data updates for CTX310 and CTX320 in the first half of the year, and a broad update on CTX112 in mid-2025. Additional updates are anticipated for CTX131 and regenerative medicine programs.

CRISPR Therapeutics has made progress in its immuno-oncology and autoimmune disease programs, with CTX112 showing strong efficacy in Phase 1/2 trials. The company also plans to expand trials for CTX112 in systemic lupus erythematosus, systemic sclerosis, and inflammatory myositis. Furthermore, advancements are being made in in vivo cardiovascular programs and regenerative medicine, including trials for Type 1 diabetes treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company dedicated to developing transformative gene-based medicines for serious diseases, announced that its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference.

The presentation is scheduled for Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the 'Events & Presentations' page in the Investors section of the company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the company's website for 14 days following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
conferences
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on gene-based medicines for serious diseases, announced the proposed election of Briggs Morrison, M.D. to its Board of Directors at the upcoming annual general meeting. CEO Samarth Kulkarni emphasized Dr. Morrison's extensive pharmaceutical industry experience and clinical development expertise as valuable assets for advancing the company's innovative platform and pipeline.

Dr. Morrison, currently the CEO and Board member of Crossbow Therapeutics, Inc., expressed enthusiasm about joining CRISPR Therapeutics. With over 30 years in the pharmaceutical and biotechnology sectors, he has held executive roles at Syndax Pharmaceuticals, AstraZeneca, Pfizer, and Merck. He has overseen clinical development from Phase 1 to approval for several drugs, including Tagrisso®, Imfinzi®, and Lynparza®.

Dr. Morrison also serves on the boards of various biotechnology companies and is an Entrepreneur Partner at MPM BioImpact. He holds a B.S. in Biology from Georgetown University and an M.D. from the University of Connecticut.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
management
-
Rhea-AI Summary

CRISPR Therapeutics presented data from their Phase 1/2 clinical trial of CTX112™, a next-generation CD19 allogeneic CAR T cell therapy, showing promising results in treating relapsed or refractory B-cell malignancies. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for treating R/R follicular lymphoma and marginal zone lymphoma.

Key findings include:

  • 67% objective response rate across all dose levels
  • 50% complete response rate
  • Well-tolerated safety profile with no Grade ≥3 infections
  • Five patients achieved responses lasting over 6 months

The trial involved 12 subjects treated with varying doses, demonstrating dose-dependent efficacy. CTX112 is also being tested in a Phase 1 trial for systemic lupus erythematosus, with potential expansion into other autoimmune indications. A broader update across indications is expected in mid-2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in the upcoming Jefferies London Healthcare Conference. CEO and Chairman Samarth Kulkarni, Ph.D., will deliver a presentation on Wednesday, November 20, 2024, at 4:00 p.m. GMT. The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section, with a replay available for 14 days afterward. CRISPR Therapeutics specializes in developing transformative gene-based medicines for serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.9%
Tags
conferences
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced that their CEO and Chairman, Samarth Kulkarni, Ph.D., will present at the Guggenheim Inaugural Healthcare Innovation Conference. The presentation is scheduled for Tuesday, November 12, 2024, at 2:00 p.m. ET.

A live webcast of the fireside chat will be accessible through the company's website's 'Events & Presentations' page in the Investors section. The webcast recording will remain available for 14 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
conferences

FAQ

What is the current stock price of Crispr Therapeut (CRSP)?

The current stock price of Crispr Therapeut (CRSP) is $33.14 as of April 1, 2025.

What is the market cap of Crispr Therapeut (CRSP)?

The market cap of Crispr Therapeut (CRSP) is approximately 2.9B.

What is CRISPR Therapeutics' primary focus?

CRISPR Therapeutics focuses on developing gene-based medicines using its proprietary CRISPR/Cas9 technology to treat serious, genetically defined diseases.

How does the CRISPR/Cas9 platform work?

The CRISPR/Cas9 platform utilizes a precise RNA-guided mechanism to target and edit specific DNA sequences, enabling precise modifications to correct genetic defects.

Which therapeutic areas does the company target?

The company’s programs span hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, cardiovascular conditions, and various rare diseases.

How does CRISPR Therapeutics generate revenue?

The company leverages a mix of in-house research and strategic collaborations with industry leaders, driving revenue through licensing arrangements, development partnerships, and commercialization of its gene editing therapies.

Who are CRISPR Therapeutics' strategic partners?

CRISPR Therapeutics collaborates with renowned companies in the biopharmaceutical sector, enhancing its R&D and commercialization capabilities through partnerships with industry leaders.

What distinguishes CRISPR Therapeutics in the competitive landscape?

Its pioneering CRISPR/Cas9 platform, robust pipeline of diverse gene editing therapies, and strategic global collaborations set it apart as an innovative and technically sophisticated player.

How does the company ensure scientific and clinical rigor?

CRISPR Therapeutics maintains a strong commitment to research excellence, incorporating extensive clinical trials and regulatory standards to ensure the safety and efficacy of its therapies.

What are the core elements of its business model?

The business model centers on leveraging a state-of-the-art gene editing platform, partnering with established industry players, and targeting therapeutic areas with high unmet needs to optimize clinical outcomes.

How is CRISPR Therapeutics contributing to innovation in medicine?

Through its disruptive gene editing technology, comprehensive clinical programs, and strategic collaborations, the company is driving forward a new class of transformative and precision-based treatments.
Crispr Therapeut

Nasdaq:CRSP

CRSP Rankings

CRSP Stock Data

2.85B
84.28M
1.67%
77.72%
24.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Switzerland
ZUG